Opthea Ltd. ADR (OPT): Price and Financial Metrics


Opthea Ltd. ADR (OPT): $4.89

-0.27 (-5.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OPT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OPT Stock Summary

  • For OPT, its debt to operating expenses ratio is greater than that reported by merely 0.51% of US equities we're observing.
  • With a price/sales ratio of 1,689.23, OPTHEA LTD has a higher such ratio than 99.67% of stocks in our set.
  • With a year-over-year growth in debt of -100%, OPTHEA LTD's debt growth rate surpasses merely 0% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to OPTHEA LTD, a group of peers worth examining would be IMMP, GOVX, ZYME, IVA, and HIMX.
  • To dig deeper into the stock's financial statements, go to OPT's page on browse-edgar?action=getcompany&CIK=0001815620.

OPT Stock Price Chart Interactive Chart >

Price chart for OPT

OPT Price/Volume Stats

Current price $4.89 52-week high $8.50
Prev. close $5.16 52-week low $4.51
Day low $4.89 Volume 2,800
Day high $5.43 Avg. volume 1,906
50-day MA $5.01 Dividend yield N/A
200-day MA $5.90 Market Cap 285.40M

Opthea Ltd. ADR (OPT) Company Bio


Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.


OPT Latest News Stream


Event/Time News Detail
Loading, please wait...

OPT Latest Social Stream


Loading social stream, please wait...

View Full OPT Social Stream

Latest OPT News From Around the Web

Below are the latest news stories about OPTHEA LTD that investors may wish to consider to help them evaluate OPT as an investment opportunity.

Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an “Ask the Expert” conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA (Wednesday 14th December 10:30am – 11:30am AEDT). Prof Slakter is a board certified Retinal and Macular Disease Specia

Yahoo | December 12, 2022

Opthea Limited's (ASX:OPT) top owners are individual investors with 44% stake, while 26% is held by hedge funds

Every investor in Opthea Limited ( ASX:OPT ) should be aware of the most powerful shareholder groups. And the group...

Yahoo | December 9, 2022

Opthea to Present at the FLORetina 2022 Congress

MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce a podium talk will be presented at the annual FLORetina congress, taking place in Rome, Italy from December 8-11, 2022. Dr. Caroline Baumal, MD from the Tufts University School of Medicine, New England Eye Center, Boston, Massachusetts will present on OPT-302 combina

Yahoo | December 6, 2022

Opthea to Present at Jefferies London Healthcare Conference

MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that Chief Executive Officer Dr. Megan Baldwin will present at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 7:25 AM GMT (6:25 PM AEDT).

GlobeNewswire | November 10, 2022

Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer

MELBOURNE, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Timothy E. Morris as Chief Financial Officer (CFO), effective 24 October 2022. Mr. Morris is a veteran pharmaceutical executive based in the U.S. with extensive industry experience leading financial teams of public and private biotechnology companies. Mr. Morris’ accomplishments include raising over $2.5 billion in equity and convertible securities for seven companies and the completion of over 95 transactions.

GlobeNewswire | October 24, 2022

Read More 'OPT' Stories Here

OPT Price Returns

1-mo 0.20%
3-mo 1.88%
6-mo -34.27%
1-year -23.59%
3-year N/A
5-year N/A
YTD -8.77%
2022 -28.96%
2021 -32.72%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7258 seconds.